Idarubicin Injection 20 mg/20 mL (3)

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

idarubicin hydrochloride, Quantity: 1 mg/mL

Available from:

Pfizer (Perth) Pty Ltd

Pharmaceutical form:

Injection, solution

Composition:

Excipient Ingredients: glycerol; hydrochloric acid; water for injections

Administration route:

Intravenous

Units in package:

1 x 20 mL

Prescription type:

(S1) This Schedule is intentionally blank

Therapeutic indications:

UK: Zavedos is used in adults and children for the treatment of acute non lymphoblastic leukaemia (ANLL), also referred to as acute myeloid leukaemia (AML). Zavedos is also used in adults and children as a second line treatment of relapsed acute lymphoblastic leukaemia (ALL)

Product summary:

Visual Identification: Red - orange, clear, mobile solution; Container Type: Vial; Container Material: PP; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Listed (Export Only)

Authorization date:

2023-02-17